Our Janssen COVID-19 Vaccine

How It Works

Our vaccine was developed using Janssen's AdVac® technology. This technology was also used to develop Janssen's European Commission-approved Ebola vaccine regimen and construct our HIV, RSV and Zika investigational vaccine candidates.

We use a piece of DNA that codes for the coronavirus "spike" and place it inside a non-replicating adenoviral vector. The vaccine cannot cause COVID-19.

Our Clinical Progress

~45,000 participants enrolled in our single-dose Phase 3 ENSEMBLE trial

Aiming for ~30,000 participants to be enrolled in our two-dose regimen Phase 3 ENSEMBLE 2 trial

ENCEMBLE Phase 3 topline data demonstrated that the vaccine candidate met primary endpoints

Vaccine Manufacturing, Supply and Access

The Company’s anticipated manufacturing timeline will enable it to meet its full year 2021 supply commitments, including those signed with governments and global organizations.

Our vaccine is estimated to remain stable for two years at -20°C / -4°F and a maximum of three months of which can be at temperatures of 2-8°C / 36°–46° F.

Transportation and storage of our vaccine is compatible with standard vaccine storage and distribution channels.

We aim to make our vaccine available on a not-for-profit basis for emergency pandemic use.

We plan to allocate up to 500 million vaccine doses to lower income countries.

J&J Works in Partnership

Johnson & Johnson is collaborating to help ensure our research platforms and outbreak expertise can be maximized to stem this pandemic. We have worked closely with clinical trial investigators and governments around the world, in addition to partnering with the Biomedical Advanced Research and Development Authority (BARDA), the National Institutes of Health (NIH) and the Beth Israel Deaconess Medical Center (BIDMC).

For more information on Johnson & Johnson’s approach to help combat COVID-19, visit jnj.com/coronavirus.

The Janssen COVID-19 Vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA) but has been authorized by FDA through an Emergency Use Authorization (EUA) for active immunization to prevent Coronavirus Disease 2019 (COVID-19) in individuals 18 years of age and older.

The emergency use of this product is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the medical product under Section 564(b)(1) of the FD&C Act, unless the declaration is terminated or authorization revoked sooner.


The COVID-19 vaccine has also been granted a Conditional/Marketing Authorization from the European Commission for use in 27 member states of the European Union (EU), plus Norway, Iceland and Liechtenstein, and has been issued an Emergency Use Listing by the World Health Organization.

For more information: https://www.jnj.com/coronavirus/customer-updates/are-you-storing-food-safely

© Johnson & Johnson Last updated: May 2021